Phase 1 Clinical Trial of Autologous Mesenchymal Stem Cell Transplantation in Multiple Sclerosis (S30.002)

Neurology ◽  
2012 ◽  
Vol 78 (Meeting Abstracts 1) ◽  
pp. S30.002-S30.002
Author(s):  
J. Cohen ◽  
A. Bar-Or ◽  
R. Bermel ◽  
E. Fisher ◽  
R. Fox ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Clinical Trial ◽  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Phase 1 ◽  
Mesenchymal Stem Cell Transplantation ◽  
Phase 1 Clinical Trial

Phase 1 Clinical Trial of Autologous Mesenchymal Stem Cell Transplantation in Multiple Sclerosis (IN8-2.003)

Neurology ◽  
2012 ◽  
Vol 78 (Meeting Abstracts 1) ◽  
pp. IN8-2.003-IN8-2.003
Author(s):  
J. Cohen ◽  
A. Bar-Or ◽  
R. Bermel ◽  
E. Fisher ◽  
R. Fox ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Clinical Trial ◽  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Phase 1 ◽  
Mesenchymal Stem Cell Transplantation ◽  
Phase 1 Clinical Trial

Autologous mesenchymal stem cell transplantation in patients with multiple sclerosis

2013 ◽  
Vol 333 ◽  
pp. e383
Author(s):  
Y. Motuzova ◽  
O. Ionova ◽  
M. Zafranskaya ◽  
A. Borisov ◽  
D. Nizheharodova ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Mesenchymal Stem Cell Transplantation

A Phase I Clinical Trial of the Treatment of Crohn's Fistula by Adipose Mesenchymal Stem Cell Transplantation

2005 ◽  
Vol 48 (7) ◽  
pp. 1416-1423 ◽  
Author(s):  
Damián García-Olmo ◽  
Mariano García-Arranz ◽  
Dolores Herreros ◽  
Isabel Pascual ◽  
Concepción Peiro ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Stem Cell Transplantation ◽  
Phase I ◽  
Cell Transplantation ◽  
Phase I Clinical Trial ◽  
Mesenchymal Stem Cell Transplantation ◽  
Crohn’S Fistula

The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group

2010 ◽  
Vol 16 (4) ◽  
pp. 503-510 ◽  
Author(s):  
Mark S Freedman ◽  
Amit Bar-Or ◽  
Harold L Atkins ◽  
Dimitrios Karussis ◽  
Francesco Frassoni ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Stem Cells ◽  
Central Nervous System ◽  
Nervous System ◽  
Mesenchymal Stem Cells ◽  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Mesenchymal Stem Cell Transplantation

Current therapies for multiple sclerosis effectively reduce inflammation, but do little in terms of repair to the damaged central nervous system. Cell-based therapies may provide a new strategy for bolstering regeneration and repair through neuro-axonal protection or remyelination. Mesenchymal stem cells modulate pathological responses in experimental autoimmune encephalitis, alleviating disease, but also stimulate repair of the central nervous system through the release of soluble factors. Autologous and allogeneic mesenchymal stem cells have been safely administered to individuals with hemato-oncological diseases and in a limited number of patients with multiple sclerosis. It is therefore reasonable to move mesenchymal stem cells transplantation into properly controlled human studies to explore their potential as a treatment for multiple sclerosis. Since it is likely that the first such studies will probably involve only small numbers of patients in a few centers, we formed an international panel comprising multiple sclerosis neurology and stem cell experts, as well as immunologists. The aims were to derive a consensus on the utilization of mesenchymal stem cells for the treatment of multiple sclerosis, along with protocols for the culture of the cells and the treatment of patients. This article reviews the consensus derived from our group on the rationale for mesenchymal stem cell transplantation, the methodology for generating mesenchymal stem cells and the first treatment protocol for multiple sclerosis patients.

Sign in / Sign up

Export Citation Format

Share Document